Holen Sie sich die Stockscreener-App
58.91
1.22%
-0.73
Vorhandelsmarkt:
58.15
-0.76
-1.29%
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt NVO?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$59.64
Offen:
$58.84
24-Stunden-Volumen:
16.11M
Relative Volume:
0.92
Marktkapitalisierung:
$261.77B
Einnahmen:
$46.69B
Nettoeinkommen (Verlust:
$15.29B
KGV:
17.16
EPS:
3.4329
Netto-Cashflow:
$9.25B
1W Leistung:
+4.14%
1M Leistung:
+17.40%
6M Leistung:
-14.55%
1J Leistung:
-27.43%
1-Tages-Spanne:
$58.34
$59.75
1-Wochen-Bereich:
$57.01
$60.64
52-Wochen-Spanne:
$43.08
$93.80
Novo Nordisk Adr Stock (NVO) Company Profile
Vergleichen Sie NVO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
58.91 | 265.01B | 46.69B | 15.29B | 9.25B | 3.4329 |
|
LLY
Lilly Eli Co
|
1,073.29 | 964.11B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
218.55 | 514.75B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
221.89 | 390.15B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
146.16 | 271.72B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
111.01 | 268.70B | 63.90B | 19.05B | 13.05B | 7.5596 |
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-08 | Herabstufung | Argus | Buy → Hold |
| 2025-10-27 | Fortgesetzt | Jefferies | Underperform |
| 2025-10-01 | Hochstufung | HSBC Securities | Hold → Buy |
| 2025-09-29 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2025-09-17 | Hochstufung | Berenberg | Hold → Buy |
| 2025-09-16 | Hochstufung | Rothschild & Co Redburn | Neutral → Buy |
| 2025-09-09 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2025-08-13 | Hochstufung | BNP Paribas Exane | Underperform → Neutral |
| 2025-08-05 | Herabstufung | UBS | Buy → Neutral |
| 2025-07-31 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-07-30 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-04-17 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2025-03-13 | Hochstufung | Kepler | Hold → Buy |
| 2025-03-03 | Herabstufung | Stifel | Buy → Hold |
| 2025-02-12 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2025-01-06 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-04-12 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-01-16 | Fortgesetzt | UBS | Neutral |
| 2023-12-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-02 | Eingeleitet | Argus | Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2022-07-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-06-28 | Herabstufung | UBS | Neutral → Sell |
| 2022-06-27 | Hochstufung | Exane BNP Paribas | Underperform → Neutral |
| 2022-06-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-05-31 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-04-25 | Hochstufung | Cowen | Market Perform → Outperform |
| 2022-04-12 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-03-16 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-01-25 | Herabstufung | Liberum | Hold → Sell |
| 2021-12-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-12-17 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2021-01-20 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-07-06 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-05-11 | Herabstufung | UBS | Buy → Neutral |
| 2020-05-04 | Eingeleitet | Cowen | Market Perform |
| 2020-03-16 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2020-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-11-18 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-09-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-08-30 | Herabstufung | Jefferies | Hold → Underperform |
| 2019-06-20 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2019-06-11 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2019-04-29 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-01-29 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2018-12-11 | Fortgesetzt | Jefferies | Hold |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2017-12-29 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2017-12-06 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2017-12-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-09-25 | Herabstufung | Exane BNP Paribas | Outperform → Neutral |
| 2017-09-06 | Hochstufung | BofA/Merrill | Underperform → Neutral |
Alle ansehen
Novo Nordisk Adr Aktie (NVO) Neueste Nachrichten
Why Eli Lilly Stock Gained 39.2% In 2025 - The Motley Fool
Can Novo Nordisk A s (b Shares) Adrhedged stock continue upward trendWeekly Loss Report & Daily Risk Controlled Trade Plans - Улправда
Novo Nordisk gets a fresh $73.50 target as Amazon starts selling the Wegovy pill - TechStock²
CICC Initiates Coverage on Novo Nordisk with Outperform Rating and $73.50 Price Target for U.S. ADRBN - marketscreener.com
European ADRs Rose In US Trading As Chip And Pharma Led - Finimize
Will Novo Nordisk A s (b Shares) Adrhedged stock benefit from infrastructure spending2026 world cup usa national team semifinals star players high defensive line winner prediction tactical review - Улправда
Novo Nordisk's Wegovy Weight Loss Pill Hits US Pharmacies With Lower Starting Cost - Sahm
G-Protein Coupled Receptors (GPCRs) Market Size to Hit USD 6.04 Billion by 2032, Growing at a CAGR of 5.59% - GlobeNewswire Inc.
2 Tailwinds Behind Novo Nordisk Stock Heading Into 2026 - Finviz
Jim Cramer Shares Key Caveat For Novo Nordisk (NVO)'s Weight Loss Pill - Finviz
FDA Approves Novo Nordisk's Wegovy Pill: A Game Changer for 2026 - Finviz
The Truth About Novo Nordisk A/S (ADR): Is Wall Street’s Favorite ‘Skinny Stock’ Still Worth t - AD HOC NEWS
Why Novo Nordisk Stock Dropped on Monday - Finviz
Where is Novo Nordisk A/S (NVO) Headed? - Finviz
Novo Nordisk Halves Wegovy Prices In China Ahead Of Generic Threat - Sahm
Novo Nordisk (NVO) Gets 9% Boost from Wegovy Pill OK - Finviz
Should You Invest in Ozempic Maker Novo Nordisk in 2026? - Finviz
The New York Stock Exchange | NYSE - NYSE
Novo Nordisk AS (NVO) Stock Price, Trades & News - GuruFocus
Why Novo Nordisk Stock Popped Today - Finviz
Novo Nordisk's Wegovy Pill Shakes Up Rivalry With Eli Lilly, Puts Health Care ETFs In Focus - Sahm
Novo Nordisk stock split: what’s next for NVO shares? - Capital.com
Eli Lilly Vs. Novo Nordisk: Which Stock Could Lead Pharma's 2026 Comeback - Sahm
Novo Nordisk Share Price Jumps After FDA Clears Wegovy Pill | Stock Market Today - Samco
Novo Nordisk surges after US approves weight loss pill - Sharecast.com
Novo Nordisk Shares Surge 7% In Tuesday Pre-Market After US FDA Approves Wegovy Pill - Sahm
Novo Nordisk stock jumps over 7% after weight loss drug Wegovy pill gets US FDA nod — Details here - livemint.com
Finanzdaten der Novo Nordisk Adr-Aktie (NVO)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.54%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):